Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

3.260 -0.010 (-0.31%)
Streaming Delayed Price Updated: 3:20 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 Next >
Cellectis to Present a Development Update for eti-cel at ASH 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Third Quarter Financial Results on November 7, 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
From Cellectis Inc.
Via GlobeNewswire
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
From Cellectis Inc.
Via GlobeNewswire
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis Reports Financial Results for the First Quarter 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report First Quarter Financial Results on May 12, 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
From Cellectis Inc.
Via GlobeNewswire
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Financial Results for the Second Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
From Cellectis Inc.
Via GlobeNewswire
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
From Cellectis Inc.
Via GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
From Cellectis Inc.
Via GlobeNewswire
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
From Cellectis Inc.
Via GlobeNewswire
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
From Cellectis Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.